Randomized Crossover of SVG101(Dispersible Tab. of Everolimus) and Afinitor 5mg in Healthy Adults

This is a randomized, open-label, single-dose, two-way cross-over study to investigate the Pharmacokinetic characteristics and safety after oral administration of SVG101 (dispersible tablet of everolimus) 5mg and Afinitor 5mg in 26 healthy volunteers.

Inclusion criteria

• Healthy adults: 19y - 55y (Male or Female)
• Male: more than 55kg, Female: more than 50kg body weight
• Body mass index: more than 18.5kg/m^2 and less than 27.0kg/m^2
• Menopause or surgical infertility female

Exclusion criteria

• Participants have or had a history of the clinically relevant disease or abnormalities in the hepatobiliary system, kidney, nervous system, immune system, respiratory system, urinary system, digestive system, endocrine system, blood/tumor, cardiovascular system, and mental illness.
• Participants with galactose intolerance, Lapp lactase deficiency, or glucose-galactose malabsorption
• Any history of gastrointestinal disease or surgery
• Participants have hypersensitive to the everolimus or other rapamycin derivatives or other components of the investigational product.
• Taking any drugs that induce or inhibit metabolizing enzymes such as barbiturate drugs within 30 days prior to first administration
• Receiving any investigational therapy of others within 180 days prior to first administration. In case of biological products, the restricted period can be extended depend on the half-life receipt product
• Pregnant or breastfeeding women